menu
Mimivax’s SurVaxM Improves Survival Time In Newly Diagnosed Glioblastoma
Mimivax’s SurVaxM Improves Survival Time In Newly Diagnosed Glioblastoma
Mimivax’s SurVaxM Improves Survival Time In Newly Diagnosed Glioblastoma

SurVaxM Highlights: ASCO 2022

Positive results from the "SURVIVE" (Phase II a) research in people with newly discovered glioblastoma were given by Mimivax (Abstract #2037).

SurVaxM mechanism of action: Immunostimulants

A cell-survival protein found in 95 percent of glioblastomas and many other malignancies, survivin is the target of SurVaxM (MimiVax), a first-in-class, proprietary peptide mimic immunogen.

The SurVaxM immunotherapy for newly diagnosed glioblastoma Phase IIa (Survive) results was presented at ASCO 2022. A total of 63 patients with freshly diagnosed glioblastoma participated in the single-arm Survive research, with a median age of 60 for those who had just undergone their first round of chemoradiation. Each patient had a craniotomy, radiation therapy, and temozolomide treatment prior to receiving the SurVaxM priming dosages. It's interesting to note that, overall, 41 percent of patients survived for at least three years after receiving a glioblastoma diagnosis and 51 percent did so for at least two years. According to the study, patients receiving standard therapy do have a 16-month median chance of survival, and the patient did well with the immunotherapy plus temozolomide.

Giving people with glioblastoma greater survival is always a step in the right direction for such a rare but fatal malignancy. "It is really encouraging to see that many patients had their tumors respond to the combination of SurVaxM and temozolomide," We're thrilled to see this encouraging treatment advance to broader studies and research into possible uses or illness situations in other settings. - Expert Verdict.

Conclusion

We anticipate a shift in the standard of care for patients with newly diagnosed glioblastoma from a monotemozolimide regimen to a combination regimen in light of the positive results of the SurvaxM ASCO 2022 trial. Additionally, SurvaxM might provide a higher standard of living and longer survival.

Other medications, such as paxalisib (Kazia Therapeutics), Efflorithine+Lomustine (Orbus), regorafenib (Bayer), and many others are also being studied for GBM.

Get in touch with our Business Expert @ Business Consulting Services | Biotech Consulting | Technical Due Diligence Firms

Trending & Popular Market Research Reports 2022 by Delveinsight

Bag3-related Gene Therapies Market

Bag3-related Gene Therapies Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Bag3-related Gene Therapies, forecasted epidemiology

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Market

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Market Insights, Market Forecast report delivers an understanding of the Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Pediatric Growth Hormone Deficiency PGHD Market

Pediatric Growth Hormone Deficiency Market Insights, Epidemiology, and Market Forecast report delivers an understanding of the Pediatric Growth Hormone Deficiency forecasted epidemiology.

SGLT2 inhibitors Market

DelveInsight's SGLT2 inhibitors Market Insights, Epidemiology, and Market Forecast report delivers an in-depth understanding of the SGLT2 inhibitors, historical and forecasted epidemiology

Reactive Airway Disease Market

Reactive Airway Disease Market report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends in the 7MM.

Carbapenem-resistant Enterobacteriaceae Infection Market

Carbapenem-resistant Enterobacteriaceae Infection Market Size, Insights report delivers an understanding of the Carbapenem-resistant Enterobacteriaceae Infection forecasted epidemiology

Oncolytic Virus Cancer Therapy Pipeline

"Oncolytic Virus Cancer Therapy" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action.

Tuberculosis Market

DelveInsight's Tuberculosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Tuberculosis, historical and forecasted epidemiology

Testicular Neoplasm Market

DelveInsight's Testicular Neoplasm Market Insights, Epidemiology, and Market Forecast report delivers an understanding forecasted epidemiology and the Testicular Neoplasm market trends in 7MM

Stem Cell Market

Stem Cell Market Research Report provides comprehensive insights into the Stem Cell Market Size, Share, Key Companies, Competitive Analysis as well as the Market Forecast

Surgical Mask & Respirator Market

Surgical Mask & Respirator Market Research Report provides comprehensive insights into the Surgical Mask & Respirator Market Size, Share, Key Companies, Competitive Analysis.

Medical Marijuana Market

DelveInsight's "Medical Marijuana Market Report 2032" offers an in-depth understanding of the Medical Marijuana epidemiology, pipeline, and market trends in the 7MM.

Hepatic Cirrhosis Market

DelveInsight's Hepatic Cirrhosis Market Insights, Epidemiology, and Market Forecast report delivers an in-depth understanding of the Hepatic Cirrhosis, historical and forecasted epidemiology

About ASCO 2022 Conference Updates

asco 2021 highlights | asco highlights 2021 | asco medical conference | asco 2021 | asco 2021 conference | when is asco 2021 | 2021 asco | 2021 asco annual meeting | asco convention | asco conference 2021 | asco 2021 | asco 21 | asco us | asco 2022 annual meeting | asco abstract 2022

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Contact Us

Yash

info@delveinsight.com